National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Dinutuximab beta EUSA for the treatment of high-risk neuroblastoma in patients ≥ 12 months, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with a history of relapsed/refractory neuroblastoma, with or without residual disease.


NCPE Assessment Process Ongoing
Rapid review commissioned 19/10/2017
Rapid review completed 23/11/2017
Rapid Review outcome Full pharmacoeconomic assessment recommended
Full pharmacoeconomic assessment commissioned by HSE 29/11/2017
Pre-submission consultation with Applicant 06/02/2018
Submission received from Applicant 11/07/2018
Current status NCPE assessment ongoing